Downloaded from: justpaste.it/92jau
Pfizer, Moderna Covid shots delay response in blood cancer patients Researchers from the Icahn School of Medicine at Mount Sinai found that almost 16 per cent of patients with multiple myeloma developed no detectable antibodies after both vaccine doses.
Covid-19 vaccines are highly effective in preventing severe infections or death, but patients with multiple myeloma -- a type of blood cancer --- are immunocompromised and often on immunosuppressive therapy. The mRNA-based Pfizer and Moderna Covid vaccines evoked a lower and delayed response in them compared to healthy people, finds a study, asserting need for monitoring or continued precautions in patients with cancers.
Researchers from the Icahn School of Medicine at Mount Sinai found that almost 16 per cent of patients with multiple myeloma developed no detectable antibodies after both vaccine doses. These findings may be relevant to other cancer patients undergoing treatment and to immunocompromised patients. The study will be published in Cancer Cell. "This study underscores the need for routine blood tests on multiple myeloma patients after vaccination to understand their risk and potential need to continue wearing masks and socially distance until the pandemic wanes," said Samir Parekh, Professor of Medicine (Hematology and Medical Oncology), and Oncological Sciences, at Mount Sinai...Read More